Ads
related to: breast cancer gene expression miner- Dosing & Administration
See Dosing Regimen & Preparation
Info For A New Treatment Option
- Adverse Reaction Data
View Common Adverse Reactions
& A Guide For Managing Them.
- Healthcare Professionals
Learn About A New TROP2-Directed
ADC For HR+ HER2- mBC.
- Request A Representative
Get More Info About A Now Approved
Treatment Option For HR+ HER2- mBC.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
The Cancer Genome Atlas →: National Cancer Institute, United States Copy number, Mutation, Methylation, Gene Expression, miRNA expression: Yes Yes Human: No Yes Yes CancerResource →: University Medicine Berlin, Germany Roche Cancer Genome Database (RCGDB) Roche Diagnostics, Penzberg, Germany Network of Cancer Genes →: King's College ...
Of note, similar gene expression patterns associated with metastatic behaviour of breast cancer tumor cells have also been found in breast cancer of dog, the most common tumor of the female dog. [5] [6] Presented below are ways that gene expression profiling has been used to more precisely classify tumors into subgroups, often with clinical effect.
Breast cancer metastatic mouse models are experimental approaches in which mice are genetically manipulated to develop a mammary tumor leading to distant focal lesions of mammary epithelium created by metastasis. Mammary cancers in mice can be caused by genetic mutations that have been identified in human cancer. This means models can be ...
Oncogenomics is a sub-field of genomics that characterizes cancer-associated genes.It focuses on genomic, epigenomic and transcript alterations in cancer. Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm formation.
A drug that interferes with this receptor may prevent or treat breast cancer. In developing a drug, one may perform gene expression profiling experiments to help assess the drug's toxicity, perhaps by looking for changing levels in the expression of cytochrome P450 genes, which may be a biomarker of drug metabolism. [2]
Expression of miR-26b is decreased in human breast cancer and seven human breast cancer cell lines, MCF7, HCC1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, BT-549 and BT-474. Overexpression of miR-26b impairs viability and triggers apoptosis of human breast cancer MCF7 cells. SLC7A11 is identified as a direct target of miR-26b and its expression is ...